Infections in Lung Allograft Recipients: Ganciclovir Era

Journal of Heart and Lung Transplantation

Volumn 27, Issue 5, 2008, Pages 528-535

  Valentine, Vincent G ^a   Bonvillain, Ryan W ^b   Gupta, Meera R ^a   Lombard, Gisele A ^a   LaPlace, Stephanie G ^c   Dhillon, Gundeep S ^d   Wang, Guoshun ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OCHSNER MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CEFAZOLIN; CLARITHROMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN; DACLIZUMAB; GANCICLOVIR; ITRACONAZOLE; METHYLPREDNISOLONE; NYSTATIN; PREDNISONE; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CANDIDIASIS; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE INFECTION; FEMALE; FOLLOW UP; FUNGUS; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION; LUNG INFECTION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MOUTH INFECTION; MYCOSIS; PATHOGENESIS; PATIENT CARE; PERITONEUM; PNEUMONIA; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SKIN INFECTION; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION; WOUND INFECTION;

ANTIVIRAL AGENTS; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; LUNG DISEASES, FUNGAL; LUNG TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; RESPIRATORY TRACT INFECTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 42649133463     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.12.013     Document Type: Article

References (30)

1. Brooks R.G., Hofflin J.M., Jamieson S.W., Stinson E.B., and Remington J.S. Infectious complications in heart-lung transplant recipients. Am J Med 79 (1985) 412-422
2. Penketh A.R., Higenbottam T.W., Hutter J., Coutts C., Stewart S., and Wallwork J. Clinical experience in the management of pulmonary opportunist infection and rejection in recipients of heart-lung transplants. Thorax 43 (1988) 762-769
3. Horvath J., Dummer S., Loyd J., et al. Infection in the transplanted and native lung after single lung transplantation. Chest 104 (1993) 681-685
4. Nicod L.P. Mechanisms of airway obliteration after lung transplantation. Proc Am Thorac Soc 3 (2006) 444-449
5. Hertz M.I., Henki C.A., Nakhleh R.E., et al. Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci 89 (1992) 10385-10389
6. Boehler A., and Estenne M. Post-transplant bronchiolitis obliterans. Eur Respir J 22 (2003) 1007-1018
7. Heyman L., Goddard M., McNiel K., Atkinson C., Sharples L.D., and Wallwork J. Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways?. Ann Thorac Surg 82 (2006) 1212-1218
8. Paradis I.L., and Williams P. Infection after lung transplantation. Semin Resp Infect 8 (1993) 207-215
9. Sole A., Morant P., Salavert M., et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
10. Mattner F., Chaberny I.F., Weissbrodt H., et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 48 suppl 1 (2005) 51-55
11. Singhal P., Usuda K., and Mehta A.C. Post-lung transplantation Aspergillus niger infection. J Heart Lung Transplant 24 (2005) 1446-1447
12. Raviv Y., Kramer M.R., Amital A., Rubinovitch B., Bishara J., and Shitrit D. Outbreak of aspergillosis infections among lung transplant recipients. Eur Soc Organ Transpl 20 (2007) 135-140
13. Westney G.E., Steven K., de Hoyos A., Chapparro C., Winton T., and Maurer J.R. Aspergillus infection in single and double lung transplant recipients. Transplantation 61 (1996) 915-919
14. Dummer J.S., Lazariashvilli N., Barnes J., Ninan M., and Milstone A.P. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 23 (2004) 1376-1381
15. Monforte V., Roman A., Gavalda J., Bravo C., Gispert P., Pahissa A., and Morell F. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients. Transplant Proc 37 (2005) 4039-4042
16. Shlobin O.A., West E.E., Lechtzin N., et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 176 (2006) 2625-2634
17. Burton C.M., Kristensen P., Lutzhoft R., et al. Cytomegalovirus infection in lung transplant recipients: the role of prophylaxis and recipient donor serotype matching. Scand J Infect Dis 38 (2006) 281-289
18. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81 (2006) 1415-1420
19. Perreas K.G., McNeil K., Charman S., Sharples L.D., Wreghitt T., and Wallwork J. Extended ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant 24 (2005) 583-587
20. Orens J.B., Estenne M., Arcasoy S., et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 745-755
21. Frost A.E. Donor criteria and evaluation. Clin Chest Med 18 (1997) 231-237
22. Struber M., Ehlers K.A., Nilsson F.N., Miller V.M., McGregor C.G., and Haverich A. Effects of lung preservation with Euro-Collins and University of Wisconsin solutions on endothelium-dependent relaxation. Ann Thorac Surg 63 (1997) 1428-1435
23. Knower M.T., Labella-Walker K., McFadden P.M., Kantrow S.P., and Valentine V.G. Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients. South Med J 93 (2000) 1087-1092
24. Valentine V.G., McFadden P.M., and Ochsner J.L. Advances in lung transplantation. Ochsner J 1 (1999) 12-18
25. Valentine V.G., Taylor D.E., Dhillon G.S., et al. Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant 21 (2002) 319-326
26. Yousem S.A., Berry G.J., Cagle P.T., et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 15 (1996) 1-15
27. Cooper J.D., Billingham M.E., Egan T., et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12 (1993) 713-716
28. Chen F., Bando T., Hanaoka N., Fukuse T., Hasegawa S., and Wada H. Early onset of ganciclovir-resistent cytomegalovirus infection in a lung transplant recipient. Jpn J Thorac Cardiovasc Surg 53 (2005) 562-564
29. Kramer M.R., Marshall S.E., Starnes V.A., Gamberg P., Amitai Z., and Theodore J. Infectious complications in heart-lung transplantation. Arch Intern Med 153 (1993) 2010-2016
30. Speich R., and van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 33 (2001) S58-S65